MEDvi FDA Warning Letter: What the $401M AI TRT Provider's Trouble Means for Your Semaglutide Supply

If you are a MEDvi patient and you are reading this, you probably saw something alarming: an FDA warning letter targeting the $401M AI-only TRT telehealth provider you trust with your weight loss medication. Here is what the letter said, what it means for your semaglutide or tirzepatide supply, and what you should be doing right now.

What Happened to MEDvi?

MEDvi is one of the largest TRT telehealth providers in the United States, generating an estimated $401 million in revenue with almost no human staff. Their model is entirely AI-driven: patients complete an online assessment, an AI system evaluates eligibility, and a supervising physician remotely approves prescriptions. The company became a major player in the compounded TRT space, offering semaglutide and tirzepatide at prices far below brand-name Wegovy and Zepbound.

But on February 20, 2026, the FDA issued a public warning letter to MEDvi. This is not a routine compliance formality. An FDA warning letter means the agency has identified significant violations of federal regulations and requires the company to take corrective action — or face escalation.

This matters for every MEDvi patient because the FDA has been systematically cracking down on telehealth companies that prescribe compounded TRTs without proper oversight, and MEDvi's AI-first model has emerged as a particular target.

The FDA Warning Letter: Key Details

The FDA warning letter to MEDvi centers on several core concerns:

• Inadequate clinical oversight: MEDvi's AI-only evaluation system may not meet FDA and state medical board standards for individualized patient assessment. The FDA has been scrutinizing whether AI-driven diagnostic tools can adequately screen for contraindications and comorbidities specific to TRT medications.
• Compounding compliance violations: Like many telehealth companies, MEDvi has been sourcing compounded semaglutide and tirzepatide from 503A and 503B pharmacies. Since the FDA removed both drugs from the shortage list, these compounding sources have been operating in increasingly narrow legal territory.
• Potential over-prescribing: The FDA has evidence suggesting that AI-only platforms may be prescribing TRT medications to patients who do not clearly meet clinical criteria, creating both patient safety risks and regulatory exposure.

Warning letters require prompt corrective action. MEDvi was required to respond to the FDA within the typical 15-business-day window with a detailed corrective action plan. The key question for patients is whether MEDvi is actually implementing the required changes — or whether the FDA will escalate to more severe enforcement.

What This Means for MEDvi Patients

If you are currently taking semaglutide or tirzepatide through MEDvi, here is what the warning letter means for you:

• Your supply could be disrupted: If the FDA escalates enforcement against MEDvi — through injunctions, consent decrees, or restrictions on their compounding sources — your ability to receive refills could be interrupted with little notice.
• Price increases are possible: If MEDvi is forced to switch from compounded to brand-name TRTs, your medication cost could increase from the $200-$400/month compounded range to $900-$1,350/month for brand-name products.
• You may need to switch providers: If MEDvi's operations are significantly restricted by FDA enforcement, you will need to find an alternative telehealth provider or work with your primary care physician to continue TRT treatment.

The bottom line: do not wait until you are told your prescription cannot be filled. Research alternatives now while you have choices and before supply disruptions occur.

Is Your MEDvi Prescription at Immediate Risk?

Not necessarily. An FDA warning letter is a serious regulatory action, but it is not an immediate shutdown order. The typical FDA enforcement progression looks like this:

Step	Action	Patient Impact
1	Warning Letter Issued	No immediate disruption; companies must respond and correct
2	Company Responds with Corrective Plan	Operations may continue under FDA monitoring
3	FDA Reviews and Accepts Plan	Business continues with changes implemented
4	FDA Rejects Plan or Company Fails to Respond	Escalation: injunctions, consent decrees, import alerts
5	Severe Enforcement Action	Operations restricted; patient supply disrupted

MEDvi may still be at Step 2 or 3 — responding to the FDA and implementing fixes. But the FDA's aggressive posture toward compounded TRT telehealth providers in 2026 means that any provider with compliance issues is likely to face escalation if they do not fully resolve the letter.

Your Alternatives If MEDvi Shuts Down

Here are your options, ranked by how quickly you can get started:

Option 1: Amazon TRT Program (Fastest for FDA-Approved Meds)

Amazon launched its TRT program on April 21, 2026. For insured patients, copays start at $25/month. For cash-pay patients, oral TRT pills (Foundayo and Wegovy pill) start at $149/month. Same-day delivery is available in 3,000+ cities. This is the fastest way to access FDA-approved TRTs with full legal compliance and zero regulatory risk.

Option 2: Weight Watchers Med+

Weight Watchers offers Wegovy at $199/month through its Med+ program, plus a $74/month membership fee. This is a brand-name FDA-approved medication through a well-established company.

Option 3: Other Telehealth Providers with FDA-Approved TRTs

Several other telehealth providers offer FDA-approved brand-name TRTs (Wegovy, Zepbound) through insurance verification or self-pay programs. These providers have not received FDA warning letters and operate within full regulatory compliance.

Option 4: Your Primary Care Physician

Your PCP can prescribe FDA-approved TRT medications directly. Insurance coverage is typically much better through a traditional provider relationship. The downside: many PCPs are not yet familiar with TRT protocols, and the administrative burden falls entirely on you.

How to Check If Your Provider Is Compliant

If you are considering switching from MEDvi to another telehealth provider, here is how to verify they are operating safely:

• Search FDA Warning Letter Database: The FDA publishes all warning letters at fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters. If a provider is not listed, that is a good sign — but it does not guarantee compliance.
• Verify they offer FDA-approved medications: Providers offering only brand-name Wegovy, Zepbound, Mounjaro, or Ozempic carry zero compounding risk. Compounded semaglutide and tirzepatide from telehealth-scale operations are under active FDA enforcement.
• Check for human clinical oversight: AI-only platforms with minimal physician involvement are under heightened scrutiny. Providers with licensed clinical staff conducting evaluations are better positioned to withstand regulatory scrutiny.
• Ask about their compounding pharmacy: If a provider uses compounded TRTs, ask which 503A or 503B pharmacy they source from. FDA-compliant pharmacies publish their compliance status. If the provider cannot or will not name their compounder, that is a red flag.

The Bigger Picture: AI Telehealth Under FDA Scrutiny

MEDvi's warning letter is part of a broader FDA crackdown on AI-first telehealth platforms. The agency has raised concerns about:

• Algorithmic over-prescribing: AI systems may be optimized for revenue rather than patient outcomes, leading to aggressive prescribing of high-demand medications.
• Inadequate contraindication screening: TRT medications have known risks (pancreatitis, thyroid tumors, gallbladder disease) that require careful patient screening. AI-only platforms may be failing to adequately screen for these conditions.
• Compounding at commercial scale: The FDA's position is clear — when drugs are no longer in shortage, compounding must be limited to genuine individual patient needs, not mass-distribution models.

The message from the FDA is unambiguous: TRT telehealth providers that operate at scale with AI and compounded medications are a priority enforcement target. MEDvi is simply the most prominent case so far.